Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Bihar, India.
Department of Radiotherapy, Mahavir Cancer Sansthan and Research Centre (MCSRC), Patna, India.
Int J Radiat Oncol Biol Phys. 2023 May 1;116(1):157-165. doi: 10.1016/j.ijrobp.2022.11.040. Epub 2022 Nov 29.
Financial toxicity has been associated with several clinical outcomes such as early mortality and poor quality of life. The aim of this study was to evaluate the magnitude of financial toxicity among radiation oncology patients and its association with health-related quality of life (HRQOL) in Indian health care settings.
This cross-sectional study was conducted among patients with cancer who had completed radiation therapy, either standalone or as part of a multimodal treatment. Financial toxicity and HRQOL were assessed using the Comprehensive Score for Financial Toxicity (COST) and Functional Assessment of Cancer Therapy: General (FACT-G) measures, respectively. Associations between financial toxicity and HRQOL were assessed using Pearson correlation. Univariate and multivariate regression analyses were conducted to identify the factors associated with financial toxicity.
A total of 350 patients were included in this study. Of the 350 participants, 57.7% were male, 95.7% had no health insurance, and 61% were diagnosed with Head & Neck cancers. The average COST score was 15.38 ± 9.18 (range, 2-35), and the average FACT-G score was 69.63 ± 12.25 (range, 33-99). Based on the total COST score, 7.4% of participants reported grade 3 and 44.9% reported grade 2 financial toxicity. A significant positive correlation was observed between the COST and FACT-G scores, with a correlation coefficient of 0.58 (P < .001), indicating a large effect size. The COST score also significantly predicted the FACT-G score (β = 0.77; 95% confidence interval [CI], 0.66-0.88; P < .001). The results of multivariate linear regression identified annual household income (β = 3.9; 95% CI, 3.29-4.57; P < .001) and cancer type (β = 3.74; 95% CI, 2.33-5.14; P < .001) as significant predictors of the COST score.
More than 80% of the participants experienced financial toxicity in this study. The results highlight the need for interventions to alleviate the growing financial toxicity among cancer survivors in India.
财务毒性与多种临床结局相关,如早期死亡率和生活质量差。本研究的目的是评估印度医疗保健环境中放射肿瘤患者财务毒性的严重程度及其与健康相关生活质量(HRQOL)的关系。
这项横断面研究是在完成放射治疗的癌症患者中进行的,单独或作为多模式治疗的一部分。使用综合财务毒性评分(COST)和癌症治疗功能评估:一般(FACT-G)量表分别评估财务毒性和 HRQOL。使用 Pearson 相关性评估财务毒性与 HRQOL 之间的关联。进行单变量和多变量回归分析,以确定与财务毒性相关的因素。
本研究共纳入 350 名患者。在 350 名参与者中,57.7%为男性,95.7%没有健康保险,61%诊断为头颈部癌症。平均 COST 评分为 15.38±9.18(范围 2-35),平均 FACT-G 评分为 69.63±12.25(范围 33-99)。根据总 COST 评分,7.4%的参与者报告 3 级和 44.9%的参与者报告 2 级财务毒性。COST 评分与 FACT-G 评分之间存在显著正相关,相关系数为 0.58(P<.001),表明效应量较大。COST 评分还显著预测了 FACT-G 评分(β=0.77;95%置信区间,0.66-0.88;P<.001)。多元线性回归的结果表明,家庭年收入(β=3.9;95%置信区间,3.29-4.57;P<.001)和癌症类型(β=3.74;95%置信区间,2.33-5.14;P<.001)是 COST 评分的显著预测因素。
在这项研究中,超过 80%的参与者经历了财务毒性。结果强调了需要采取干预措施来减轻印度癌症幸存者日益严重的财务毒性。